CD163 and systemic-onset juvenile idiopathic arthritis: Bleesing et al. demonstrated soluble IL-2 receptor α chain (sIL-Rα, or sCD25) and soluble CD163 (sCD163) to be significantly higher in the acute phase of MAS compared to untreated new-onset sJIA patients [25].